Benzinga | Sep 16, 2020 08:01AM EDT

Biocept Says Has Received Over 35,000 COVID-19 Specimens To Date, Has Distributed ~83,000 Collection Kits

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ --Biocept, Inc. (NASDAQ:BIOC),a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has received more than 35,000 COVID-19 specimens to date for processing through its RT-PCR technology at its CLIA-certified, CAP-accredited high-complexity molecular lab and expects to collect an average reimbursement of approximately $100 per test. The Company has distributed approximately 83,000 COVID-19 PCR specimen collection kits to date, and has inventory for approximately 87,000 additional collection kits.